- 2026/06/08 Telomelysin (OBP-301) Officially Obtains Manufacturing and Marketing Approval in Japan
- 2026/06/03 Phase 1b/2a Clinical Trial Application Submitted to PMDA for a New OBP-301 Indication
- 2026/06/01 Announcement that the Company's Accumulated Disposal of Securities Has Reached the Public Announcement Standard
- 2026/05/26 Announcement of Important Resolutions from the 2026 Shareholders' Meeting of the Company
- 2026/05/22 Update on OBP-301: Conclusions from the Japanese MHLW Subcommittee Meeting
- 2026/05/14 The Progress Update of the New Drug under Development, OBP-301
- 2026/05/12 The Company's 2026 Q1 Consolidated Financial Statements Have been Approved by the Board of Directors
- 2026/05/04 Announcement of the Date of the Board of Directors Meeting for the First Quarter of 2026 Financial Report
- 2026/04/30 Results of Phase II Clinical Trial of OBP-301 Presented in the International Oncolytic Virus Conference (IOVC)
- 2026/04/23 The Progress Update of the New Drug under Development, OBP-301